Impel NeuroPharma Inc. (IMPL) Launches 3M Share Proposed Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Impel NeuroPharma Announces Launch of Proposed Public Offering
September 7, 2021 4:01 PM EDTSEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock. All of the shares of common stock are being offered by Impel. In addition, Impel intends to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock at the offering price, less underwriting discounts and... More
